Brought to you by 
CAT/OGS merger withdrawn
24 Apr 2003
Executive Summary
Monoclonal antibody company Cambridge Antibody Technology Group is acquiring fellow UK drug company Oxford GlycoSciences in a stock deal valued at approximately £114.6mm ($185.6mm). For every outstanding OGS share, CAT will pay 0.362 share of its own stock, currently worth £2.06 ($3.33), a 28% premium to OGS's market average. OGS shareholders will own about 35.7% of the combined company, which will be renamed.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Withdrawn
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
CAT/OGS merger withdrawn
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice